Basic Info

3 Forbes Road
Lexington, MA 02421
  N/A
  N/A
  N/A
Preferred contact:
  N/A - President/CEO
Aquila Biopharmaceuticals Inc
Profile last edited on: 8/1/2008
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
In November 2000 Antigenics Inc. (Nasdaq: AGEN) of New York acquired Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA). Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders. The company’s lead product candidate is Oncophage, a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanoma

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
CD1 Presented Vaccines to Prevent Chlamydia Infection
Lipid-Based Vaccines For Staphylococcus Aureus

      

Media coverage